Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HNSA | Stockholm | SEK | Real-time | |
HNSAs | BATS Europe | SEK | Delayed | |
24H | Frankfurt | EUR | Delayed |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States.The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Gunnar Tufveson | - | - | Chairman of European Medical Advisory Board in Transplantation |
Stanley Jordan | - | - | Chairman of US Medical Advisory Board in Transplantation |
Peter Nicklin | 60 | 2022 | Independent Chairman of the Board |
Christophe Legendre | - | - | Member of European Medical Advisory Board in Transplantation |
Kathryn Wood | - | - | Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation |
Robert A. Montgomery | - | - | Member of US Medical Advisory Board in Transplantation |
Anders Gersel Pedersen | 73 | 2018 | Independent Director |
Eva Nilsagard | 60 | 2019 | Independent Director |
Mats Peter Blom | 59 | 2019 | Independent Director |
Hilary M. Malone | 59 | 2021 | Independent Director |
Florian Nicolas Christian Reinaud | 51 | 2024 | Director |
Jonas Wikstrom | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review